HENDERSON, Nev.–(BUSINESS WIRE)–Paysign, Inc. (NASDAQ: PAYS), a leading provider of patient affordability programs, donor compensation solutions, engagement andHENDERSON, Nev.–(BUSINESS WIRE)–Paysign, Inc. (NASDAQ: PAYS), a leading provider of patient affordability programs, donor compensation solutions, engagement and

Paysign, Inc. to Present at the Oppenheimer 11th Annual Emerging Growth Conference

HENDERSON, Nev.–(BUSINESS WIRE)–Paysign, Inc. (NASDAQ: PAYS), a leading provider of patient affordability programs, donor compensation solutions, engagement and management platforms and integrated payment processing for the life sciences industries, today announced it will be presenting at the Oppenheimer 11th Annual Emerging Growth Conference to be held February 3-4, 2026, through a virtual format.

The focus of the virtual conference is to feature one-on-one and small group meetings with emerging companies in technology, industrial growth and consumer sectors. Paysign’s Chief Financial Officer, Jeff Baker, will host one-on-one meetings on Tuesday, February 3.

Investors interested in registering may contact their Oppenheimer representative.

About Paysign

Paysign, Inc. (NASDAQ: PAYS) operates at the intersection of fintech and healthcare, integrating advanced payment processing and program management with tailored technologies for the plasma, pharmaceutical and life sciences industries. Their breakthrough patient affordability solutions ensure patients receive the financial assistance they need to adhere to prescribed therapies by mitigating the effects of copay accumulators and maximizers. Paysign specializes in blood and plasma donor compensation programs, as well as comprehensive engagement and management platforms optimized for life sciences. Paysign’s proprietary processing architecture supports physical, virtual, mobile and bank-based payments with real-time transaction intelligence, enabling efficient, compliant and scalable program delivery. Through advanced reporting, analytics and in-house 24/7 bilingual customer support, Paysign delivers measurable value, exceptional service and a superior experience for donors, patients, healthcare providers, pharmaceutical manufacturers and program sponsors across their growing fintech healthcare ecosystem. The company is committed to improving efficiencies, reducing costs, streamlining communications, increasing program performance and providing actionable insights to those they serve.

Forward-Looking Statements

Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the companies, are forward-looking statements that involve risks and uncertainties. There is no assurance that such statements will prove to be accurate, and actual results and future events could differ materially. Paysign undertakes no obligation to publicly update or revise any statements in this release, whether as a result of new information, future events or otherwise.

Contacts

Investor Relations
ir@paysign.com
888.522.4853

paysign.com/investors

Media Relations
Alicia Ches

888.522.4850

pr@paysign.com

Market Opportunity
WorldAssets Logo
WorldAssets Price(INC)
$0.6866
$0.6866$0.6866
-8.22%
USD
WorldAssets (INC) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vitalik Buterin Withdraws 16,384 ETH to Fund Open-Source Technology and Privacy Projects

Vitalik Buterin Withdraws 16,384 ETH to Fund Open-Source Technology and Privacy Projects

TLDR: Buterin withdrew 16,384 ETH to personally fund open-source projects as Ethereum Foundation reduces spending.  The initiative supports secure hardware, privacy
Share
Blockonomi2026/01/30 16:39
What is the most promising crypto right now? A practical checklist

What is the most promising crypto right now? A practical checklist

Crypto interest often spikes after headlines. This guide helps everyday readers turn curiosity into repeatable checks that limit obvious execution risks. We focus
Share
Coinstats2026/01/30 15:52
Inside Upexi’s SOL play: staking yield and locked token deals

Inside Upexi’s SOL play: staking yield and locked token deals

The post Inside Upexi’s SOL play: staking yield and locked token deals appeared on BitcoinEthereumNews.com. Upexi is the largest public company holding Solana tokens and uses a SOL strategy to build its holdings and generate additional revenue through staking. In an interview with crypto.news, Upexi CEO Allan Marshall explains why the company executed a large equity private placement to build a crypto treasury, citing MicroStrategy’s playbook and a more accommodating U.S. policy backdrop. Summary Upexi is the largest public holder of Solana, using equity raises to build a SOL treasury and earn staking yield. Upexi CEO Allan Marshall spoke with crypto.news in an interview. Corporate strategy focuses on accretive issuances, staking, and discounted locked SOL purchases, not venture investing. Upexi markets itself as a “new institutional gateway to Solana’s (SOL) speed, scale, and rapidly growing ecosystem.” But it isn’t alone, as it joins a handful of rival companies also building Solana treasuries, while dozens of other public entities are focusing on other coins. Speaking to crypto.news, Marshall discusses strategy and market perception. He notes that Upexi is focused on accretive capital raises, staking, and discounted, locked SOL purchases rather than venture investing. He also discusses how the company measures progress through an “adjusted SOL per share” metric designed to remove timing and leverage effects. We also discuss the company’s risk management strategies, which include a buy-and-hold approach, no hedging, disciplined use of leverage, and custody with qualified providers. The entire interview transcript is below: crypto.news: Upexi is now the largest corporate holder of Solana with over 2 million SOL in treasury. Why did you make such a dramatic shift now? Was there something specific that happened in the past few months that gave you the confidence to commit so heavily to a crypto treasury at this time? Allan Marshall: Upexi did the first large-scale equity private placement to create an altcoin treasury, and there were…
Share
BitcoinEthereumNews2025/09/20 02:51